Vitamin K2 MK-7: Benefits for Bone & Arteries — A Research-Backed Guide
⚡ 60-Second Summary
Vitamin K2 MK-7 (Menaquinone-7) is a fat-soluble vitamin that activates two critical calcium-regulating proteins: osteocalcin in bone (which locks calcium into the bone matrix) and Matrix Gla Protein (MGP) in arterial walls (which prevents calcium from depositing in soft tissue). It is the long-chain, fermentation-derived form of K2 with a 72-hour half-life — far superior for daily dosing compared to the short-acting MK-4 form.
Best form: Fermentation-derived MK-7 (from natto or bacillus subtilis) for documented bone and vascular outcomes. Synthetic MK-7 (from geranylgeranyl diphosphate) is biochemically equivalent but less studied clinically.
Typical dose: 90–200 µg/day with a fat-containing meal (K2 is fat-soluble). Stack with vitamin D3 for calcium direction. Critical: do not take if on Warfarin or other vitamin K antagonists without physician supervision.
Do not confuse with: Vitamin K2 MK-4 (different form, shorter half-life, much higher dose required) or vitamin K1 (phylloquinone, primarily for blood clotting).
What is Vitamin K2 MK-7?
Vitamin K is a family of fat-soluble vitamins that share a naphthoquinone ring but differ in their side chains. The two main dietary forms are K1 (phylloquinone), found in leafy greens and best known for its role in blood clotting, and K2 (menaquinones), found in fermented foods and some animal products, with a primary role in calcium metabolism.
K2 itself is a family of compounds numbered by the length of their side chain — MK-4 through MK-13. MK-7 (Menaquinone-7) is the form produced in the highest concentrations by Bacillus subtilis natto during the fermentation of soybeans into natto, a traditional Japanese food. This fermentation origin gives MK-7 a distinct biological profile from the shorter MK-4 form that is biosynthesized in animal tissues (and synthesized industrially from geranylgeranyl diphosphate).
The key pharmacokinetic advantage of MK-7 is its extraordinary half-life of approximately 72 hours, compared to just 1–4 hours for MK-4. This means a single daily dose of 90–200 µg MK-7 maintains stable serum concentrations and biological activity, whereas MK-4 requires doses of 1,500–45,000 µg/day split across multiple meals to achieve comparable effects.
Vitamin K2 acts as a cofactor for gamma-glutamyl carboxylase, the enzyme that converts glutamate residues in vitamin K-dependent proteins to gamma-carboxyglutamate (Gla). This carboxylation step is essential for activating several proteins critical to calcium handling:
- Osteocalcin — the most abundant non-collagen protein in bone; carboxylated osteocalcin binds calcium and hydroxyapatite to mineralize the bone matrix
- Matrix Gla Protein (MGP) — expressed in vascular smooth muscle cells and cartilage; carboxylated MGP is one of the most potent known inhibitors of vascular calcification
- Protein S and Protein C — anticoagulant proteins (explaining the Warfarin interaction)
- Gas6 — involved in cell survival and growth signaling
Dietary MK-7 is found almost exclusively in natto (~900–1,000 µg per 100 g). Other fermented foods (hard cheeses, fermented dairy) provide smaller amounts of longer-chain menaquinones (MK-8, MK-9). Most Western diets provide very little K2 overall.
Evidence-based benefits of Vitamin K2 MK-7
1. Bone mineral density and fracture risk reduction
Osteocalcin must be carboxylated (activated) by vitamin K2 to bind calcium and incorporate it into bone mineral. Uncarboxylated osteocalcin (ucOC) is a validated biomarker of vitamin K2 insufficiency. In the pivotal VitaK-CAC trial and the MK-7 bone RCT by Knapen et al. (2013) — a three-year placebo-controlled trial in 244 healthy postmenopausal Dutch women — 180 µg/day of MK-7 significantly reduced the age-related decline in bone mineral density at the lumbar spine and femoral neck, and significantly reduced ucOC levels, indicating full K2-dependent protein carboxylation. A 2019 meta-analysis of 19 RCTs confirmed that menaquinone supplementation significantly improves bone mineral density and reduces fracture incidence, with MK-7 trials showing the most consistent outcomes.
2. Vascular calcification prevention (Matrix Gla Protein activation)
MGP is the primary local inhibitor of arterial calcification. In its uncarboxylated, inactive form (dp-ucMGP), it cannot bind calcium crystals and vascular calcification proceeds uninhibited. Large observational studies show that dp-ucMGP levels — a biomarker of K2 status — inversely predict cardiovascular events and arterial stiffness. The VitaK-CAC trial (Vermeer et al.) found that 180 µg/day MK-7 for 3 years significantly reduced progression of coronary artery calcification in healthy postmenopausal women, particularly those with existing calcification. A 2015 RCT by Knapen et al. showed that 180 µg/day MK-7 improved arterial stiffness markers over 3 years.
3. Rotterdam Study: cardiovascular mortality (prospective cohort)
See the dedicated section below. This is the landmark population study establishing the MK-7 / cardiovascular disease link.
4. Synergy with vitamin D3 for calcium direction
Vitamin D3 dramatically upregulates intestinal calcium absorption and raises serum calcium. It also upregulates osteocalcin and MGP gene expression — but both proteins require K2 to be activated. Without adequate K2, the proteins are synthesized but remain uncarboxylated and non-functional. This creates a mechanistic rationale — and growing clinical evidence — for co-supplementing D3 and K2 together. A 2019 RCT (van Ballegooijen et al.) showed that D3+K2 co-supplementation improved carboxylation status of both osteocalcin and MGP better than either alone. See Vitamin D3 and magnesium for the full bone stack context.
5. Possible benefit in type 2 diabetes (osteocalcin-insulin axis)
Carboxylated osteocalcin has an endocrine role: undercarboxylated osteocalcin acts as a hormone stimulating pancreatic beta-cell proliferation and insulin secretion. K2 supplementation reduces ucOC and may modestly improve insulin sensitivity. A 2020 RCT (Yoshida et al.) found MK-7 improved glycemic markers in postmenopausal women. Evidence is promising but not yet sufficient to make a diabetes-management claim.
The Rotterdam Study: landmark evidence
The most influential piece of population evidence for K2 is the Rotterdam Study analysis published by Geleijnse et al. in 2004 (Journal of Nutrition), which followed 4,807 Dutch adults aged 55+ for 10 years. Key findings:
- High dietary menaquinone (K2) intake — primarily from cheese — was associated with a 57% reduced risk of dying from coronary heart disease, a 52% reduced risk of all-cause mortality, and reduced risk of severe aortic calcification.
- Dietary phylloquinone (K1) showed no significant cardiovascular association.
- The effect was dose-dependent and significant after adjustment for cardiovascular risk factors.
- The menaquinone intake driving the association was primarily MK-8 and MK-9 from cheese — but the mechanism (MGP activation) is the same for MK-7, which has higher biological potency per microgram.
As a cohort study, this cannot prove causation. But combined with the mechanistic evidence for MGP activation and subsequent RCT data on arterial calcification, it provides strong support for the K2 cardiovascular hypothesis.
MK-7 vs MK-4 and other vitamin K2 forms
Supplement labels can be confusing. Here is a direct comparison of the most commercially relevant K2 forms:
| Form | Half-life | Typical effective dose | Source | Notes |
|---|---|---|---|---|
| MK-7 (fermentation-derived) | ~72 hours | 90–200 µg/day | Natto / B. subtilis natto fermentation | Best pharmacokinetics for once-daily dosing. Most RCT evidence for bone and vascular outcomes. The gold standard for supplementation. |
| MK-7 (synthetic) | ~72 hours | 90–200 µg/day | Chemical synthesis (geranylgeranyl diphosphate) | Biochemically identical to fermentation-derived MK-7. Less clinical trial data specifically using synthetic material, but pharmacokinetics are equivalent. |
| MK-4 | 1–4 hours | 1,500–45,000 µg/day (split doses) | Synthetic; also in meat/dairy/eggs | Requires much higher doses for equivalent biological effect. Used in Japanese pharmaceutical trials (Menatetrenone) at pharmacological doses (15–45 mg/day) for osteoporosis treatment. Over-the-counter supplement doses of 100–500 µg are pharmacologically irrelevant. |
| MK-8, MK-9 | Intermediate | Not standardized | Fermented cheese, sauerkraut | Present in diet; drove much of the Rotterdam Study signal. Not commonly available as standalone supplements. |
| Vitamin K1 (Phylloquinone) | ~1–2 hours | 90–120 µg/day (AI) | Leafy greens (kale, spinach, broccoli) | Primary role in blood coagulation (hepatic factors II, VII, IX, X). Limited extrahepatic distribution. Does not efficiently activate MGP in arterial walls. A different compound with different functions. |
Important: If you see a product labeled simply "Vitamin K2" without specifying MK-7, check the supplement facts. Many older products contain MK-4 at doses (100–500 µg) that are too low to produce meaningful biological effects at that form's pharmacokinetics. Always verify "MK-7" and the microgram dose.
How much Vitamin K2 MK-7 should you take?
There is no established RDA for vitamin K2 specifically. Guidance for MK-7:
- General bone and vascular health: 90–120 µg/day — the dose used in the Knapen 3-year bone RCT and sufficient to fully suppress ucOC in most adults
- Higher-risk individuals / co-supplementing high-dose D3: 150–200 µg/day — used in multiple intervention trials; ensures MGP carboxylation is not limiting
- Therapeutic (Japanese pharmacological use for osteoporosis): 15,000–45,000 µg/day MK-4 (menatetrenone) — a prescription drug in Japan; not achievable with MK-7 supplementation and not an appropriate comparison
- No established UL in healthy adults: Up to 360 µg/day MK-7 has been used in trials without adverse events; doses above this have not been systematically studied
Timing: Take with the largest fat-containing meal of the day. MK-7 is fat-soluble and absorption is enhanced by dietary fat. Taking it with the D3 supplement (usually at the same meal) is convenient and mechanistically rational.
Monitoring: In research settings, ucOC and dp-ucMGP are used as biomarkers of K2 adequacy. These are not widely available in standard clinical labs, but their normalization in most people occurs at 90–180 µg/day MK-7.
Safety and side effects
Vitamin K2 MK-7 has an excellent safety profile in healthy adults. No Tolerable Upper Intake Level has been established because adverse effects have not been observed at any supplemental dose in anticoagulant-free individuals.
Common side effects (rare)
- Mild GI upset in a small percentage of users — take with food to minimize
- Headache reported anecdotally at very high doses
Who should exercise caution
- Warfarin and K-antagonist anticoagulant users — see interactions section; this is the primary safety concern
- People taking other anticoagulants (rivaroxaban, apixaban, dabigatran — the direct oral anticoagulants) — these do not work through vitamin K and do not interact with K2, but discuss with your cardiologist before adding any new supplement
- Hypercalcemia — K2 promotes calcium utilization; theoretically relevant but no cases documented at supplemental doses
- Soy or natto allergy — fermentation-derived MK-7 is produced from soybeans; people with soy allergy should use synthetic MK-7 or verify allergen-free production
Pregnancy and breastfeeding
K2 at typical dietary and supplemental doses is considered safe in pregnancy. Newborns receive vitamin K1 (not K2) injections at birth to prevent hemorrhagic disease of the newborn — this is unrelated to maternal K2 supplementation. No teratogenicity signals have been identified with MK-7. However, data specific to high-dose K2 supplementation in pregnancy are limited; discuss with your OB if you are supplementing above dietary amounts.
Drug and nutrient interactions
CRITICAL: Warfarin and vitamin K antagonists
This is the most important interaction in all of K2 supplementation. Warfarin (Coumadin), acenocoumarol, phenprocoumon, and related drugs work by blocking vitamin K epoxide reductase — the enzyme that recycles vitamin K after it acts as a carboxylase cofactor. Supplementing vitamin K2 MK-7 directly antagonizes Warfarin's mechanism, raising clotting factor activity and lowering the INR (international normalized ratio) toward the non-therapeutic range.
Even modest, inconsistent K2 supplementation can cause dangerous INR fluctuation. If you take any vitamin K antagonist anticoagulant, do not supplement K2 without physician supervision and frequent INR monitoring. Some anticoagulation clinics use a strategy of consistent, fixed K2 intake to stabilize INR — but this requires close medical management.
Vitamin D3 — synergistic (desired)
As described above, D3 and K2 act in complementary roles in calcium metabolism. Their combination is generally recommended for anyone supplementing either at significant doses. See Vitamin D3 for D3-specific dosing guidance.
Calcium supplements — interaction to be aware of
Calcium supplementation raises the importance of adequate K2 (and D3). Without K2-mediated MGP activation, supplemental calcium may be more likely to deposit in arterial walls. Evidence is not definitive, but the precautionary principle supports co-supplementing K2 with calcium.
Bile acid sequestrants (cholestyramine, colestipol)
These drugs reduce fat absorption and will reduce absorption of fat-soluble vitamins including K2. If you take a bile acid sequestrant, take K2 at a separate meal or discuss supplementation needs with your physician.
Orlistat
This weight-loss drug blocks fat absorption and will reduce K2 absorption substantially. K2 (and all fat-soluble vitamins) should be supplemented separately from orlistat doses.
Who might benefit — and who shouldn't bother
| Most likely to benefit | Unlikely to benefit or should avoid |
|---|---|
| Postmenopausal women concerned about bone density loss | People taking Warfarin or other vitamin K antagonists (without physician supervision) |
| Anyone already supplementing significant vitamin D3 (≥2,000 IU/day) | People eating natto regularly (already getting abundant MK-7 from diet) |
| People with low dietary K2 intake (no fermented foods, little cheese) | Children and adolescents without clinical indication (insufficient pediatric data) |
| Adults with known vascular calcification or at elevated cardiovascular risk | People relying solely on K1 (phylloquinone) for extrahepatic K2 functions — K1 does not efficiently substitute for K2 in MGP or osteocalcin activation |
| People taking calcium supplements wanting to optimize where that calcium goes | Anyone expecting MK-4 products at 100–500 µg doses to substitute — check your label for MK-7 specifically |
Frequently asked questions
How much Vitamin K2 MK-7 should I take per day?
90–200 µg/day covers most adults' needs. Start at 90–120 µg and increase to 150–200 µg if taking high-dose D3 (≥3,000 IU/day) or if you have significant cardiovascular calcification risk. Take with a fat-containing meal for best absorption.
Can I take Vitamin K2 MK-7 if I take Warfarin?
Only under physician supervision with INR monitoring. K2 directly antagonizes Warfarin's mechanism. Even small supplemental doses can destabilize INR control and create bleeding or clotting risk. This is not a minor interaction — it is a contraindication without medical management.
What is the difference between MK-7 and MK-4?
Both are vitamin K2, but MK-7 has a 72-hour half-life (once-daily dosing at 90–200 µg) versus MK-4's 1–4 hours (requiring 1,500–45,000 µg/day split doses). Most modern bone and vascular RCTs use MK-7. Low-dose MK-4 supplements (100–500 µg) are pharmacologically irrelevant at MK-4's kinetics.
Should I take K2 with vitamin D3?
Yes — this is one of the most well-supported co-supplementation combinations. D3 drives calcium absorption; K2 activates the proteins that direct calcium to bone and away from arteries. The two vitamins work through complementary mechanisms. Take them together with a fat-containing meal.
Is natto-derived MK-7 better than synthetic?
Pharmacokinetically they are equivalent — both are all-trans MK-7 with the same half-life and biological activity. Natto-derived MK-7 has slightly more clinical trial history. Those with soy allergy should use synthetic MK-7 or verify allergen-free status on natto-derived products.
Will K2 MK-7 interfere with blood thinners like rivaroxaban or apixaban?
Direct oral anticoagulants (DOACs) like rivaroxaban, apixaban, and dabigatran do not work through vitamin K and do not interact with K2 supplementation the way Warfarin does. However, always inform your prescriber before adding any new supplement.
Related ingredients and articles
Vitamin D3
K2's most important synergistic partner for calcium direction and bone health.
Vitamin K2 MK-4
The shorter-chain K2 form: when it's used, and how it compares to MK-7.
Magnesium
The third pillar of bone health alongside D3 and K2.
Best Bone Supplements (2026)
How calcium, magnesium, vitamin D, K2, and boron fit together.
Disclaimer: This information is for educational purposes only and should not replace medical advice. Always consult a qualified healthcare provider before starting any supplement, especially if you have a medical condition, are pregnant, or take prescription medications. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.